# US 2023/0414579 A1 · Pharmaceuticals for covid19 treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414579 A1
- Document ID: US20230414579A1
- Status: Published application
- Kind: A1
- Application number: 18/248,278
- Filed: 2021-10-07
- Published: 2023-12-28
- Earliest claimed: 2020-10-15
- Assignees: NantCell, Inc.
- Applicants: Nantcell, Inc.
- Inventors: Oleksandr BUZKO; Shiho TANAKA; Kayvan NIAZI
- Web page: https://patentgrep.com/patent/US20230414579A1

## CPC

- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/07: Tetrapeptides
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of treatment for COVID19.

## Claims

### Claim 1

A method of treating a SARS-CoV-2 virus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a drug selected from the group consisting of piperacillin or a salt thereof, N-[4-[1-(1,4-dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-N′-methylurea or a salt thereof, and cefoperazone or a salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the piperacillin or salt thereof is administered in the amount of about 2 g to about 40 g powder per injection.

### Claim 3 (depends on 2)

The method of claim 2, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 4 (depends on 1)

The method of claim 1, wherein the N-[4-[1-(1,4-dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-N′-methylurea or salt thereof is administered in the amount of about 5 mg/kg to about 50 mg/kg.

### Claim 5 (depends on 4)

The method of claim 4, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cefoperazone or salt thereof is administered in the amount of about 1 g to about 12 g per day.

### Claim 7 (depends on 6)

The method of claim 6, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 8

A method of treating a SARS-CoV-2 virus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a drug selected from the group consisting of cilengitide or a salt thereof and hederacoside or a salt thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cilengitide or salt thereof is administered in the amount of about 30 mg/m2 to about 2400 mg/m2 body surface area.

### Claim 10 (depends on 9)

The method of claim 9, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 11 (depends on 8)

The method of claim 8, wherein the hederacoside or salt thereof is administered in the amount of about 35 mg/kg to about 50 mg/kg.

### Claim 12 (depends on 11)

The method of claim 11, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 13

A method of treating a SARS-CoV-2 virus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a drug selected from the group consisting of (R,S)-ivosidenib or a salt thereof, evacetrapib or a salt thereof, idasanutlin or a salt thereof, and relugolix or a salt thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the (R,S)-ivosidenib or salt thereof is administered in the amount of about 200 mg to about 1200 mg per day.

### Claim 15 (depends on 14)

The method of claim 14, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 16 (depends on 13)

The method of claim 13, wherein the evacetrapib or salt thereof is administered in the amount of about 30 mg to about 600 mg per day.

### Claim 17 (depends on 16)

The method of claim 16, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 18 (depends on 13)

The method of claim 13, wherein the idasanutlin or salt thereof is administered in the amount of about 120 to about 300 mg per day.

### Claim 19 (depends on 18)

The method of claim 18, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.

### Claim 20 (depends on 13)

The method of claim 13, wherein the relugolix or salt thereof is administered in the amount of about 20 to about 360 mg per day.

### Claim 21 (depends on 20)

The method of claim 20, further comprising administering one or more agents selected from the group consisting of convalescent plasma, anti-SARS-CoV-2 antibodies or antibody-like molecules, tocilizumab, acalabrutinib, tofacitinib, ruxolitinib, baricitinib, anakinra, canakinumab, apremilast, mavrilimumab, sarilumab, VIR-7831, REGN-COV2, LY-CoV555, immune system modulators, interferons and interferon-like molecules, anticoagulants, prone positioning, antiviral therapeutics, remdesivir, lopinavir, ritonavir, oseltamivir, favipiravir, umifenovir, colchicine, ivermectin, antibacterial therapeutics, nitazoxanide, steroids, corticosteroids, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, non-steroidal anti-inflammatories, calpain protease inhibitors, cathespin protease inhibitors, famotidine, nafamostat, camostat, ascorbic acid, zinc, RLF-100, tradipitant, LAU-7b, HFB30132A, AZD7442, CAP-1002, brilacidin, STI-1499, ebselen, disulfiram, tideglusib, carmofur, shikonin, PX-12, N3 and anti-SARS-CoV-2 vaccines.
